The Role of Neural Network for the Detection of Parkinson's Disease: A Scoping Review

Late feature fusion using neural network with voting classifier for Parkinson's disease detection

Parkinson's disease (PD) is classified as a neurological, progressive illness brought on by cell death in the posterior midbrain. Early PD detection will assist doctors in reducing the disease's consequences. A collection of skilled models that may be applied to regression as well as classification is known as artificial intelligence (AI). PD can be detected using a variety of dataset formats, including text, speech, and picture datasets. For the purpose of classifying Parkinson's disease, this study suggests merging deep with machine learning recognition approaches. The three primary components of the suggested approach are designed to enhance the accuracy of Parkinson's disease early diagnosis. These sections cover the topics of categorising, combining, and separating. Convolutional Neural Networks (CNN) as well as attention procedures are used to create feature extractors. The related motion signals are fed to a combination of convolutional neural network and long-short-memory model for feature extraction. Besides, for the classification of patients from non-suffers of Parkinson's disease, Random Forest, Logistic Regression, Support Vector Machine, Extreme Boot Classifier, and voting classifier were used. Our result shows that for the PD handwriting and related motion datasets, using the proposed CNN with an attention and voting classifier yields 99.95% accuracy, 99.99% precision, 99.98% sensitivity, and 99.95% F1-score. Based on these results, it is warranted to conclude that the proposed methodology of feature extraction from photos of handwriting and relating motor symptoms, fusing of those features, and following it with a voting classifier yields excellent results for PD classification.

Artificial intelligence in Parkinson's disease: Early detection and diagnostic advancements

Parkinson's disease (PD) is the second most common neurodegenerative disorder, globally affecting men and women at an exponentially growing rate, with currently no cure. Disease progression starts when dopaminergic neurons begin to die. In PD, the loss of neurotransmitter, dopamine is responsible for the overall communication of neural cells throughout the body. Clinical symptoms of PD are slowness of movement, involuntary muscular contractions, speech & writing changes, lessened automatic movement, and chronic tremors in the body. PD occurs in both familial and sporadic forms and modifiable and non-modifiable risk factors and socioeconomic conditions cause PD. Early detectable diagnostics and treatments have been developed in the last several decades. However, we still do not have precise early detectable biomarkers and therapeutic agents/drugs that prevent and/or delay the disease process. Recently, artificial intelligence (AI) science and machine learning tools have been promising in identifying early detectable markers with a greater rate of accuracy compared to past forms of treatment and diagnostic processes. Artificial intelligence refers to the intelligence exhibited by machines or software, distinct from the intelligence observed in humans that is based on neural networks in a form and can be used to diagnose the longevity and disease severity of disease. The term Machine Learning or Neural Networks is a blanket term used to identify an emerging technology that is created to work in the way of a "human brain" using many intertwined neurons to achieve the same level of raw intelligence as that of a brain. These processes have been used for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, to assess the severity of the patient's condition. In the current article, we discuss the prevalence and incidence of PD, and currently available diagnostic biomarkers and therapeutic strategies. We also highlighted currently available artificial intelligence science and machine learning tools and their applications to detect disease and develop therapeutic interventions.

Segmentation of Substantia Nigra in Brain Parenchyma Sonographic Images Using Deep Learning

Currently, Parkinson's Disease (PD) is diagnosed primarily based on symptoms by experts clinicians. Neuroimaging exams represent an important tool to confirm the clinical diagnosis. Among them, Brain Parenchyma Sonography (BPS) is used to evaluate the hyperechogenicity of Substantia Nigra (SN), found in more than 90% of PD patients. In this article, we exploit a new dataset of BPS images to investigate an automatic segmentation approach for SN that can increase the accuracy of the exam and its practicability in clinical routine. This study achieves state-of-the-art performance in SN segmentation of BPS images. Indeed, it is found that the modified U-Net network scores a Dice coefficient of 0.859 ± 0.037. The results presented in this study demonstrate the feasibility and usefulness of SN automatic segmentation in BPS medical images, to the point that this study can be considered as the first stage of the development of an end-to-end CAD (Computer Aided Detection) system. Furthermore, the used dataset, which will be further enriched in the future, has proven to be very effective in supporting the training of CNNs and may pave the way for future studies in the field of CAD applied to PD.

Parkinson's Disease Detection from Voice Recordings Using Associative Memories

Parkinson's disease (PD) is a neurological condition that is chronic and worsens over time, which presents a challenging diagnosis. An accurate diagnosis is required to recognize PD patients from healthy individuals. Diagnosing PD at early stages can reduce the severity of this disorder and improve the patient's living conditions. Algorithms based on associative memory (AM) have been applied in PD diagnosis using voice samples of patients with this health condition. Even though AM models have achieved competitive results in PD classification, they do not have any embedded component in the AM model that can identify and remove irrelevant features, which would consequently improve the classification performance. In this paper, we present an improvement to the smallest normalized difference associative memory (SNDAM) algorithm by means of a learning reinforcement phase that improves classification performance of SNDAM when it is applied to PD diagnosis. For the experimental phase, two datasets that have been widely applied for PD diagnosis were used. Both datasets were gathered from voice samples from healthy people and from patients who suffer from this condition at an early stage of PD. These datasets are publicly accessible in the UCI Machine Learning Repository. The efficiency of the ISNDAM model was contrasted with that of seventy other models implemented in the WEKA workbench and was compared to the performance of previous studies. A statistical significance analysis was performed to verify that the performance differences between the compared models were statistically significant. The experimental findings allow us to affirm that the proposed improvement in the SNDAM algorithm, called ISNDAM, effectively increases the classification performance compared against well-known algorithms. ISNDAM achieves a classification accuracy of 99.48%, followed by ANN Levenberg-Marquardt with 95.89% and SVM RBF kernel with 88.21%, using Dataset 1. ISNDAM achieves a classification accuracy of 99.66%, followed by SVM IMF1 with 96.54% and RF IMF1 with 94.89%, using Dataset 2. The experimental findings show that ISNDAM achieves competitive performance on both datasets and that statistical significance tests confirm that ISNDAM delivers classification performance equivalent to that of models published in previous studies.

Imperative Role of Machine Learning Algorithm for Detection of Parkinson’s Disease: Review, Challenges and Recommendations

Parkinson’s disease (PD) is a neurodegenerative disease that affects the neural, behavioral, and physiological systems of the brain. This disease is also known as tremor. The common symptoms of this disease are a slowness of movement known as ‘bradykinesia’, loss of automatic movements, speech/writing changes, and difficulty with walking at early stages. To solve these issues and to enhance the diagnostic process of PD, machine learning (ML) algorithms have been implemented for the categorization of subjective disease and healthy controls (HC) with comparable medical appearances. To provide a far-reaching outline of data modalities and artificial intelligence techniques that have been utilized in the analysis and diagnosis of PD, we conducted a literature analysis of research papers published up until 2022. A total of 112 research papers were included in this study, with an examination of their targets, data sources and different types of datasets, ML algorithms, and associated outcomes. The results showed that ML approaches and new biomarkers have a lot of promise for being used in clinical decision-making, resulting in a more systematic and informed diagnosis of PD. In this study, some major challenges were addressed along with a future recommendation.

Deep Learning Paradigm for Cardiovascular Disease/Stroke Risk Stratification in Parkinson's Disease Affected by COVID-19: A Narrative Review

Background and Motivation: Parkinson's disease (PD) is one of the most serious, non-curable, and expensive to treat. Recently, machine learning (ML) has shown to be able to predict cardiovascular/stroke risk in PD patients. The presence of COVID-19 causes the ML systems to become severely non-linear and poses challenges in cardiovascular/stroke risk stratification. Further, due to comorbidity, sample size constraints, and poor scientific and clinical validation techniques, there have been no well-explained ML paradigms. Deep neural networks are powerful learning machines that generalize non-linear conditions. This study presents a novel investigation of deep learning (DL) solutions for CVD/stroke risk prediction in PD patients affected by the COVID-19 framework. Method: The PRISMA search strategy was used for the selection of 292 studies closely associated with the effect of PD on CVD risk in the COVID-19 framework. We study the hypothesis that PD in the presence of COVID-19 can cause more harm to the heart and brain than in non-COVID-19 conditions. COVID-19 lung damage severity can be used as a covariate during DL training model designs. We, therefore, propose a DL model for the estimation of, (i) COVID-19 lesions in computed tomography (CT) scans and (ii) combining the covariates of PD, COVID-19 lesions, office and laboratory arterial atherosclerotic image-based biomarkers, and medicine usage for the PD patients for the design of DL point-based models for CVD/stroke risk stratification. Results: We validated the feasibility of CVD/stroke risk stratification in PD patients in the presence of a COVID-19 environment and this was also verified. DL architectures like long short-term memory (LSTM), and recurrent neural network (RNN) were studied for CVD/stroke risk stratification showing powerful designs. Lastly, we examined the artificial intelligence bias and provided recommendations for early detection of CVD/stroke in PD patients in the presence of COVID-19. Conclusion: The DL is a very powerful tool for predicting CVD/stroke risk in PD patients affected by COVID-19.

Machine Learning Classifiers to Evaluate Data From Gait Analysis With Depth Cameras in Patients With Parkinson's Disease

Introduction

The assessments of the motor symptoms in Parkinson's disease (PD) are usually limited to clinical rating scales (MDS UPDRS III), and it depends on the clinician's experience. This study aims to propose a machine learning technique algorithm using the variables from upper and lower limbs, to classify people with PD from healthy people, using data from a portable low-cost device (RGB-D camera). And can be used to support the diagnosis and follow-up of patients in developing countries and remote areas.

Methods

We used Kinect®eMotion system to capture the spatiotemporal gait data from 30 patients with PD and 30 healthy age-matched controls in three walking trials. First, a correlation matrix was made using the variables of upper and lower limbs. After this, we applied a backward feature selection model using R and Python to determine the most relevant variables. Three further analyses were done using variables selected from backward feature selection model (Dataset A), movement disorders specialist (Dataset B), and all the variables from the dataset (Dataset C). We ran seven machine learning models for each model. Dataset was divided 80% for algorithm training and 20% for evaluation. Finally, a causal inference model (CIM) using the DoWhy library was performed on Dataset B due to its accuracy and simplicity.

Results

The Random Forest model is the most accurate for all three variable Datasets (Dataset A: 81.8%; Dataset B: 83.6%; Dataset C: 84.5%) followed by the support vector machine. The CIM shows a relation between leg variables and the arms swing asymmetry (ASA) and a proportional relationship between ASA and the diagnosis of PD with a robust estimator (1,537).

Conclusions

Machine learning techniques based on objective measures using portable low-cost devices (Kinect®eMotion) are useful and accurate to classify patients with Parkinson's disease. This method can be used to evaluate patients remotely and help clinicians make decisions regarding follow-up and treatment.

Cardiovascular/Stroke Risk Stratification in Parkinson's Disease Patients Using Atherosclerosis Pathway and Artificial Intelligence Paradigm: A Systematic Review

Parkinson’s disease (PD) is a severe, incurable, and costly condition leading to heart failure. The link between PD and cardiovascular disease (CVD) is not available, leading to controversies and poor prognosis. Artificial Intelligence (AI) has already shown promise for CVD/stroke risk stratification. However, due to a lack of sample size, comorbidity, insufficient validation, clinical examination, and a lack of big data configuration, there have been no well-explained bias-free AI investigations to establish the CVD/Stroke risk stratification in the PD framework. The study has two objectives: (i) to establish a solid link between PD and CVD/stroke; and (ii) to use the AI paradigm to examine a well-defined CVD/stroke risk stratification in the PD framework. The PRISMA search strategy selected 223 studies for CVD/stroke risk, of which 54 and 44 studies were related to the link between PD-CVD, and PD-stroke, respectively, 59 studies for joint PD-CVD-Stroke framework, and 66 studies were only for the early PD diagnosis without CVD/stroke link. Sequential biological links were used for establishing the hypothesis. For AI design, PD risk factors as covariates along with CVD/stroke as the gold standard were used for predicting the CVD/stroke risk. The most fundamental cause of CVD/stroke damage due to PD is cardiac autonomic dysfunction due to neurodegeneration that leads to heart failure and its edema, and this validated our hypothesis. Finally, we present the novel AI solutions for CVD/stroke risk prediction in the PD framework. The study also recommends strategies for removing the bias in AI for CVD/stroke risk prediction using the PD framework.

Mining imaging and clinical data with machine learning approaches for the diagnosis and early detection of Parkinson's disease

Parkinson’s disease (PD) is a common, progressive, and currently incurable neurodegenerative movement disorder. The diagnosis of PD is challenging, especially in the differential diagnosis of parkinsonism and in early PD detection. Due to the advantages of machine learning such as learning complex data patterns and making inferences for individuals, machine-learning techniques have been increasingly applied to the diagnosis of PD, and have shown some promising results. Machine-learning-based imaging applications have made it possible to help differentiate parkinsonism and detect PD at early stages automatically in a number of neuroimaging studies. Comparative studies have shown that machine-learning-based SPECT image analysis applications in PD have outperformed conventional semi-quantitative analysis in detecting PD-associated dopaminergic degeneration, performed comparably well as experts’ visual inspection, and helped improve PD diagnostic accuracy of radiologists. Using combined multi-modal (imaging and clinical) data in these applications may further enhance PD diagnosis and early detection. To integrate machine-learning-based diagnostic applications into clinical systems, further validation and optimization of these applications are needed to make them accurate and reliable. It is anticipated that machine-learning techniques will further help improve differential diagnosis of parkinsonism and early detection of PD, which may reduce the error rate of PD diagnosis and help detect PD at pre-motor stage to make it possible for early treatments (e.g., neuroprotective treatment) to slow down PD progression, prevent severe motor symptoms from emerging, and relieve patients from suffering.

Bias Investigation in Artificial Intelligence Systems for Early Detection of Parkinson's Disease: A Narrative Review

Background and Motivation: Diagnosis of Parkinson's disease (PD) is often based on medical attention and clinical signs. It is subjective and does not have a good prognosis. Artificial Intelligence (AI) has played a promising role in the diagnosis of PD. However, it introduces bias due to lack of sample size, poor validation, clinical evaluation, and lack of big data configuration. The purpose of this study is to compute the risk of bias (RoB) automatically.

METHOD

The PRISMA search strategy was adopted to select the best 39 AI studies out of 85 PD studies closely associated with early diagnosis PD. The studies were used to compute 30 AI attributes (based on 6 AI clusters), using AP(ai)Bias 1.0 (AtheroPointTM, Roseville, CA, USA), and the mean aggregate score was computed. The studies were ranked and two cutoffs (Moderate-Low (ML) and High-Moderate (MH)) were determined to segregate the studies into three bins: low-, moderate-, and high-bias.

RESULT

The ML and HM cutoffs were 3.50 and 2.33, respectively, which constituted 7, 13, and 6 for low-, moderate-, and high-bias studies. The best and worst architectures were "deep learning with sketches as outcomes" and "machine learning with Electroencephalography," respectively. We recommend (i) the usage of power analysis in big data framework, (ii) that it must undergo scientific validation using unseen AI models, and (iii) that it should be taken towards clinical evaluation for reliability and stability tests.

CONCLUSION

The AI is a vital component for the diagnosis of early PD and the recommendations must be followed to lower the RoB.